Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,650 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations.
Wei TH, Wang ZX, Lu MY, Xu YJ, Yang J, Ni XF, Cheng Y, Zhang MY, Liu JC, Li QQ, Cai J, Chen ZJ, Kang JB, Li N, Dai WC, Ding N, Yu YC, Leng XJ, Xue X, Wang XL, Sun SL, Yang Y, Li NG, Shi ZH. Wei TH, et al. Among authors: leng xj. J Med Chem. 2024 Sep 11. doi: 10.1021/acs.jmedchem.4c00529. Online ahead of print. J Med Chem. 2024. PMID: 39258312
A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48).
Leng X, Leszczyński P, Jeka S, Liu S, Liu H, Miakisz M, Gu J, Kilasonia L, Stanislavchuk M, Yang X, Zhou Y, Dong Q, Mitroiu M, Addison J, Rezk MF, Zeng X. Leng X, et al. Arthritis Res Ther. 2024 Sep 7;26(1):157. doi: 10.1186/s13075-024-03375-w. Arthritis Res Ther. 2024. PMID: 39244595 Free PMC article. Clinical Trial.
1,650 results